Sage slips as Huntington’s Disease therapy fails in mid-stage trial
koto_feja
Shares of Sage Therapeutics (NASDAQ:SAGE) fell in the premarket on Wednesday after the company said dalzanemdor, its candidate for an inherited neurological condition called Huntington’s Disease, failed in a mid-stage trial.
The 12-week DIMENSION study evaluated how dalzanemdor, also known as SAGE-718, will impact cognitive impairment found in 189 HD patients.
Citing its topline data, the company said dalzanemdor didn’t lead to a statistically significant difference versus placebo on the Symbol Digit Modalities Test, a clinical measure used as the trial’s primary endpoint.
Sage (NASDAQ:SAGE) said there were no statistically significant differences versus placebo for secondary endpoints either. Given the setback, the company will halt further R&D efforts related to dalzanemdor.
As a result, SAGE’s ongoing PURVIEW safety trial, designed to test the candidate among HD patients, will also come to an end.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10